XTRA:DMP

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. More Details


Snowflake Analysis

Reasonable growth potential with mediocre balance sheet.

Share Price & News

How has Dermapharm Holding's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: DMP is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: DMP's weekly volatility (6%) has been stable over the past year.


Market Performance


7 Day Return

1.8%

DMP

1.5%

DE Pharmaceuticals

1.0%

DE Market


1 Year Return

48.0%

DMP

-3.6%

DE Pharmaceuticals

3.8%

DE Market

Return vs Industry: DMP exceeded the German Pharmaceuticals industry which returned -4.9% over the past year.

Return vs Market: DMP exceeded the German Market which returned 2.8% over the past year.


Shareholder returns

DMPIndustryMarket
7 Day1.8%1.5%1.0%
30 Day31.7%11.7%13.8%
90 Day19.3%0.2%1.9%
1 Year50.7%48.0%-0.5%-3.6%7.1%3.8%
3 Yearn/a26.5%11.9%5.2%-3.9%
5 Yearn/a26.5%5.0%27.5%9.5%

Long-Term Price Volatility Vs. Market

How volatile is Dermapharm Holding's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Dermapharm Holding undervalued compared to its fair value and its price relative to the market?

9.2%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: DMP (€54.9) is trading below our estimate of fair value (€60.48)

Significantly Below Fair Value: DMP is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: DMP is poor value based on its PE Ratio (37x) compared to the XE Pharmaceuticals industry average (23.6x).

PE vs Market: DMP is poor value based on its PE Ratio (37x) compared to the German market (23.1x).


Price to Earnings Growth Ratio

PEG Ratio: DMP is poor value based on its PEG Ratio (1.7x)


Price to Book Ratio

PB vs Industry: DMP is overvalued based on its PB Ratio (9.9x) compared to the DE Pharmaceuticals industry average (6.2x).


Next Steps

Future Growth

How is Dermapharm Holding forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

22.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DMP's forecast earnings growth (22.3% per year) is above the savings rate (0.2%).

Earnings vs Market: DMP's earnings (22.3% per year) are forecast to grow slower than the German market (26.9% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: DMP's revenue (6.7% per year) is forecast to grow faster than the German market (5.9% per year).

High Growth Revenue: DMP's revenue (6.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: DMP's Return on Equity is forecast to be high in 3 years time (30.4%)


Next Steps

Past Performance

How has Dermapharm Holding performed over the past 5 years?

10.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DMP has high quality earnings.

Growing Profit Margin: DMP's current net profit margins (10.3%) are lower than last year (10.9%).


Past Earnings Growth Analysis

Earnings Trend: DMP's earnings have grown by 10.3% per year over the past 5 years.

Accelerating Growth: DMP's earnings growth over the past year (8.8%) is below its 5-year average (10.3% per year).

Earnings vs Industry: DMP earnings growth over the past year (8.8%) underperformed the Pharmaceuticals industry 13.1%.


Return on Equity

High ROE: Whilst DMP's Return on Equity (26.61%) is high, this metric is skewed due to their high level of debt.


Next Steps

Financial Health

How is Dermapharm Holding's financial position?


Financial Position Analysis

Short Term Liabilities: DMP's short term assets (€412.0M) exceed its short term liabilities (€134.2M).

Long Term Liabilities: DMP's short term assets (€412.0M) do not cover its long term liabilities (€783.6M).


Debt to Equity History and Analysis

Debt Level: DMP's debt to equity ratio (199.7%) is considered high.

Reducing Debt: DMP's debt to equity ratio has reduced from 437.2% to 199.7% over the past 5 years.

Debt Coverage: DMP's debt is not well covered by operating cash flow (17.1%).

Interest Coverage: DMP's interest payments on its debt are well covered by EBIT (14.2x coverage).


Balance Sheet


Next Steps

Dividend

What is Dermapharm Holding current dividend yield, its reliability and sustainability?

1.46%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: DMP's dividend (1.46%) is higher than the bottom 25% of dividend payers in the German market (1.15%).

High Dividend: DMP's dividend (1.46%) is low compared to the top 25% of dividend payers in the German market (3.65%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, DMP has been paying a dividend for less than 10 years.

Growing Dividend: DMP's dividend payments have increased, but the company has only paid a dividend for 2 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (53.9%), DMP's dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: DMP's dividends in 3 years are forecast to be well covered by earnings (48.4% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.1yrs

Average management tenure


CEO

Hans-George Feldmeier

no data

Tenure

Dr. Hans-George Feldmeier is the Chief Executive Officer and Chairman of the Management Board at Dermapharm Holding SE and also serves as Member of the Management Board from August 2017.


Leadership Team

NamePositionTenureCompensationOwnership
Hans-George Feldmeier
CEO & Chairman of the Management Boardno datano datano data
Hilde Neumeyer
CFO & Member of the Management Board0.33yrno datano data
Karin Samusch
Member of the Management Board & Chief Business Development Officer3.25yrsno datano data
Jürgen Ott
Chief Marketing Officer & Member of Management Board1.08yrsno datano data

1.1yrs

Average Tenure

Experienced Management: DMP's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Dermapharm Holding SE's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Dermapharm Holding SE
  • Ticker: DMP
  • Exchange: XTRA
  • Founded: 1991
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €3.013b
  • Shares outstanding: 53.84m
  • Website: https://www.ir.dermapharm.de

Number of Employees


Location

  • Dermapharm Holding SE
  • Lil-Dagover-Ring 7
  • Grünwald
  • Bavaria
  • 82031
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DMPDB (Deutsche Boerse AG)YesBearer SharesDEEURFeb 2018
DMPXTRA (XETRA Trading Platform)YesBearer SharesDEEURFeb 2018
DMPDBATS-CHIXE (BATS 'Chi-X Europe')YesBearer SharesGBEURFeb 2018
0A5JLSE (London Stock Exchange)YesBearer SharesGBEURFeb 2018

Biography

Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three segments: Branded Pharmaceuticals...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/12/01 19:12
End of Day Share Price2020/12/01 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.